title: Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
authors.affiliation: Epatologia e Gastroenterologia, Ospedale Niguarda Cà Granda, Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Mancuso
authors.forename: C
authors.initials: C
authors.lastname: Zavaglia
authors.forename: F
authors.initials: F
authors.lastname: Bai
authors.forename: M
authors.initials: M
authors.lastname: Puoti
authors.forename: L S
authors.initials: LS
authors.lastname: Belli
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib